Company overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing COLL with another company.
| Daily close (USD) | $22.11 |
| Market capitalization (USD) | $719,804,603.43 |
| Price / earnings (TTM) | 15.02 |
| Price / book | 2.31 |
No matching rows. Clear the filter to see all records.
Read COLL's valuation metrics
Company size
Collegium Pharmaceutical, Inc. Common Stock's recorded market capitalization is $719,804,603.43. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
COLL's recorded P/E is 15.02: about $15.02 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
COLL's recorded price-to-book ratio is 2.31. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Collegium Pharmaceutical, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about COLL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow COLL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.